Nanobody modified high-performance AIE photosensitizer nanoparticles for precise photodynamic oral cancer therapy of patient-derived tumor xenograft

Wenbo Wu,Leilei Shi,Yukun Duan,Shidang Xu,Lingyue Shen,Ting Zhu,Lidan Hou,Xiangjun Meng,Bin Liu
DOI: https://doi.org/10.1016/j.biomaterials.2021.120870
IF: 14
2021-07-01
Biomaterials
Abstract:<p>Photodynamic therapy (PDT) is a promising noninvasive treatment option for patients suffering from superficial tumors, such as oral cancer. However, for photosensitizers (PSs), it remains a grand challenge to simultaneously excel in all the key performance indicators including effective singlet oxygen (<sup>1</sup>O<sub>2</sub>) generation under clinical laser, specific targeting function and stable far-red (FR)/near-infrared (NIR) emission with low dark toxicity. In addition, traditional PS nanoparticles (NPs) for clinical use suffer from quenched fluorescence and reduced <sup>1</sup>O<sub>2</sub> production caused by molecular aggregation. To address these issues, AIEPS5 with aggregation-induced FR/NIR emission and effective <sup>1</sup>O<sub>2</sub> generation under 532 nm laser irradiation is designed by precise optimization of the chemical structure. By attaching a polyethylene glycol (PEG) chain onto AIEPS5, the yielded amphiphilic AIEPS5-PEG2000 can spontaneously self-assemble into water dispersible NPs, which are further endowed with targeted delivery function <em>via</em> the decoration of anti-Her-2 nanobody (NB). The bespoke AIEPS5-NPs-NB exhibit effective <sup>1</sup>O<sub>2</sub> generation capability, bright FR/NIR emission centered at 680 nm, and negligible dark toxicity, which outperform Heimbofen, a clinically approved PS in PDT using a patient-derived tumor xenograft model.</p>
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?